Ocular Therapeutix announced that the SOL‑1 Phase 3 superiority trial for its wet age‑related macular degeneration (AMD) therapy AXPAXLI met its primary endpoint, with 74.1% of treatment‑naïve patients achieving the required visual‑acuity improvement at week 36. The study, the only FDA‑aligned Phase 3 comparison of a single AXPAXLI injection to a single aflibercept injection, demonstrated that AXPAXLI outperformed the standard anti‑VEGF therapy, positioning the drug as the first product in the market to claim superiority and potentially enabling premium pricing and physician preference.
The success validates Ocular Therapeutix’s bioresorbable hydrogel platform, which delivers a tyrosine‑kinase inhibitor directly to the eye for a sustained effect. By showing superiority over aflibercept, the trial supports the company’s strategy to capture a larger share of the $15 billion wet AMD market and to pursue a 505(b)(2) regulatory pathway that could expedite approval. The data also reinforce the company’s narrative that a single annual dose could reduce treatment burden for patients and clinicians.
Financially, Ocular Therapeutix reported a net loss of $265.9 million for the full year 2025, up from $193.5 million in 2024, while revenue fell to $52.0 million from $63.7 million. The decline reflects a challenging reimbursement environment for its DEXTENZA product line, but the company’s cash balance of $737.1 million, raised through a recent equity offering, provides a runway through 2028 to support pre‑commercialization investments for AXPAXLI.
In a statement, CEO Pravin U. Dugel said, "We are thrilled to report today's historic data that position AXPAXLI to potentially become one of the most consequential advances in retina. The SOL‑1 data provide robust evidence that support AXPAXLI's potential to deliver safe, durable, and clinically significant visual and anatomic outcomes with a meaningfully reduced treatment burden." He added that demonstrating superiority against aflibercept was an exceptionally difficult bar, underscoring the trial’s significance.
Despite the positive clinical data, the market reaction was muted, with analysts noting that investors remained cautious about the company’s broader financial performance and the potential regulatory hurdles ahead. The company’s revenue decline and ongoing net losses, coupled with the high cost of bringing a new drug to market, tempered enthusiasm for the trial’s commercial prospects.
Looking ahead, Ocular Therapeutix plans to submit a New Drug Application for AXPAXLI based on the SOL‑1 data and to continue the SOL‑R non‑inferiority study, which will evaluate a six‑month re‑dosing paradigm. The company’s substantial cash reserves and the trial’s success position it to pursue regulatory approval and eventual commercialization, while the market will likely monitor how the company translates clinical superiority into market share and profitability.
The content on EveryTicker is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.